Posttransplant MRD and T-cell chimerism status predict outcomes in patients allografted with AML/MDS
| Autor: | Justin Loke, Nicholas McCarthy, Aimee E Jackson, Shamyla Siddique, Andrea Hodgkinson, John Mason, Charles R Crawley, Maria Gilleece, Andrew J Peniket, Rachel Protheroe, Rahuman Salim, Eleni Tholouli, Keith WIlson, Georgia Andrew, Richard Dillon, Naeem Khan, Victoria Potter, Pramila Krishnamurthy, Charles Craddock, Sylvie D Freeman |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Blood Advances. |
| ISSN: | 2473-9537 2473-9529 |
| Popis: | Allogeneic stem-cell transplantation allows the delivery of curative graft-versus-leukemia (GVL) in patients with acute myeloid leukemia/myelodysplasia (AML/MDS). Surveillance of T-cell chimerism, measurable residual disease (MRD) and blast HLA-DR expression may inform whether GVL effectiveness is reduced. We report the prognostic impact of these biomarkers in patients allografted for AML/MDS. 187 patients from FIGARO, a randomized trial of reduced-intensity conditioning regimens in AML/MDS, were alive and relapse-free, at the first MRD timepoint and provided bone marrow for flow cytometric MRD monitoring and blood samples for T-cell chimerism analysis, requested to month+12. 29 (15.5%) patients had at least one MRD-positive result post-transplant. MRD-positivity was associated with reduced overall survival (OS) (HR:2.18, p=0.0028) as a time-varying Cox variable and remained significant irrespective of pre-transplant MRD status in multivariate analyses (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|